Metronidazole Noridem (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms where it is reduced to reactive nitro radicals that damage DNA and inhibit nucleic acid synthesis, leading to cell death. This selective activation in low‑oxygen environments provides its antibacterial and antiprotozoal activity.

The dosing regimen is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and other clinical factors. The product is supplied as an intravenous solution and the prescriber specifies the infusion rate and total daily dose.

Metronidazole is classified as Pregnancy Category B, indicating no evidence of risk in animal studies and insufficient human data; it may be used when the potential benefit justifies the risk. Small amounts are excreted in breast milk, so breastfeeding mothers should consult their healthcare provider.

Enquiries are submitted via the product page on gnhindia.com, where the required quantity is entered. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metronidazole is a nitroimidazole with strong activity against obligate anaerobes and certain protozoa, often preferred for its oral and intravenous formulations. Alternatives such as clindamycin or beta‑lactam‑beta‑lactamase inhibitor combinations may be used, but metronidazole offers a distinct mechanism and generally lower risk of Clostridioides difficile overgrowth.

The product should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Vials must be kept upright, inspected for particulate matter before use, and discarded according to local regulations after the expiry date.

Metronidazole Noridem is supplied as a sterile intravenous solution. It is infused into a vein over a period specified by the prescriber, typically diluted in compatible IV fluids. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious adverse reactions include seizures, severe allergic responses such as anaphylaxis or Stevens‑Johnson syndrome, peripheral neuropathy, pancytopenia and hepatic toxicity. Patients should be monitored for neurological symptoms, skin reactions and abnormal laboratory values during therapy.

Individuals with a known hypersensitivity to metronidazole or other nitroimidazoles should avoid the product. Caution is advised in patients with severe hepatic impairment, central nervous system disorders, or those receiving disulfiram, as adverse reactions may be heightened.